Abstract:Background Ischemic stroke frequently leads to a condition known as post-stroke cognitive impairment (PSCI). Timely recognition of individuals susceptible to developing PSCI could facilitate the implementation of personalized strategies to mitigate cognitive deterioration. High mobility group box 1 (HMGB1) is a protein released by ischemic neurons and implicated in inflammation after stroke. Circulating levels of HMGB1 could potentially serve as a prognostic indicator for the onset of cognitive impairment following ischemic stroke. Objective To investigate the predictive value of circulating HMGB1 concentrations in the acute phase of ischemic stroke for the development of cognitive dysfunction at the 3-month follow-up. Methods A total of 192 individuals experiencing their initial episode of acute cerebral infarction were prospectively recruited for this longitudinal investigation. Concentrations of circulating HMGB1 were quantified using an enzyme-linked immunosorbent assay (ELISA) technique within the first 24 hours following hospital admission. Patients underwent neurological evaluation including NIHSS scoring. Neuropsychological evaluation was conducted at the 3-month follow-up after the cerebrovascular event, employing the Montreal Cognitive Assessment (MoCA) as the primary tool for assessing cognitive performance. Multivariable logistic regression models were employed to investigate the relationship between circulating HMGB1 concentrations and cognitive dysfunction following stroke, which was operationalized as a MoCA score below 26, while controlling for potential confounders including demographic characteristics, stroke severity, vascular risk factors, and laboratory parameters. Results Of 192 patients, 84 (44%) developed PSCI. Circulating HMGB1 concentrations were significantly elevated in individuals who developed cognitive dysfunction following stroke compared to those who maintained cognitive integrity (8.4 ± 1.2 ng/mL vs 4.6 ± 0.5 ng/mL, respectively; p < 0.001). The prevalence of PSCI showed a dose-dependent increase with higher HMGB1 quartiles. After controlling for potential confounders such as demographic factors (age, gender, and education), stroke severity, vascular risk factors, and laboratory parameters in a multivariable logistic regression model, circulating HMGB1 concentrations emerged as a significant independent predictor of cognitive dysfunction following stroke (regression coefficient = 0.236, p < 0.001). Conclusion Circulating HMGB1 concentrations quantified within the first 24 hours following acute cerebral infarction are significantly and independently correlated with the likelihood of developing cognitive dysfunction at the 3-month follow-up, even after accounting for potential confounding factors. HMGB1 may be a novel biomarker to identify patients likely to develop post-stroke cognitive impairment for targeted preventive interventions.

Serum Rheumatoid Factor Levels at Acute Phase of Ischemic Stroke Are Associated with Poststroke Cognitive Impairment.

Low Serum Superoxide Dismutase is Associated with a High Risk of Cognitive Impairment after Mild Acute Ischemic Stroke

Serum Retinoic Acid Level and the Risk of Poststroke Cognitive Impairment in Ischemic Stroke Patients.

Associations of Rheumatoid Factor, Rheumatoid Arthritis, and Interleukin-6 Inhibitor with the Prognosis of Ischemic Stroke: a Prospective Multicenter Cohort Study and Mendelian Randomization Analysis

Raised high-sensitivity C-reactive protein and cognitive impairment among African stroke survivors within the first three months following stroke

Abstract 15908: A Meta-Analysis Revealing an Association Between High Sensitivity C-Reactive Protein Levels and Cognitive Impairment After 3-Months of Ischemic Stroke

Elevated Serum Amyloid A is Associated with Cognitive Impairment in Ischemic Stroke Patients

Serum Matrix Metalloproteinase-9 And Cognitive Impairment After Acute Ischemic Stroke

Serum lipid levels and 3-month prognosis in Chinese patients with acute stroke

Decreased plasma Aβ levels were not associated with post‐stroke cognitive impairment: Biomarkers (non‐neuroimaging) / plasma/serum/urine biomarkers

Elevated C-Reactive Protein and Depressed High-Density Lipoprotein Cholesterol are Associated with Poor Function Outcome after Ischemic Stroke.

Vascular Risk Factors Aggravate Cognitive Impairment in First‐ever Young Ischaemic Stroke Patients

High-Serum Brain-Derived Neurotrophic Factor Levels Are Associated With Decreased Risk of Poststroke Cognitive Impairment

Serum Uric Acid and High-Sensitivity C-Reactive Protein As Predictors of Cognitive Impairment in Patients with Cerebral Infarction

Serum CRP concentrations and severity of ischemic stroke subtypes.

Association between serum non-high-density lipoprotein cholesterol and cognitive impairment in patients with acute ischemic stroke

Circulating HMGB1 in acute ischemic stroke and its association with post-stroke cognitive impairment

C-Reactive Protein Levels and Cognitive Decline following Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

The Serum Interleukin-18 is a Potential Marker for Development of Post-Stroke Depression

Combination of Serum Neurofilament Light Chain Levels and MRI Markers to Predict Cognitive Function in Ischemic Stroke

Serum levels of homocysteine at admission are associated with post-stroke depression in acute ischemic stroke